bpc-157 body protection compound gastric pentadecapeptide human clinical trial gut Stable BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future bpc-157 human clinical trial BPC 157 (Body Protection Compound

In SURMOUNT-1, the most common treatment-emergent adverse events were gastrointestinal: nausea (24.6-33.3% across doses vs 9.5% placebo), diarrhea (18.7-21.2%), vomiting (5.7-12.2%), and constipation (5.8-11.5%)

The 20mg/ml concentration eliminates the need for split injections

Hypokalemia and thrombocytosis could occur upon conversion of severe megaloblastic to normal erythropoiesis with B12 therapy

Other therapies included Alemtuzumab, Natalizumab, and Ofatumumab

Conversely, if you accidentally add extra water, every dose is weaker

They may offer significant effects in lowering inflammation, improving tissue and bone repair, supporting brain health, and other areas